U.S. health secretary says AstraZeneca trial in United States remains on hold: CNBC




  • In US
  • 2020-09-23 12:59:13Z
  • By Reuters
U.S. health secretary says AstraZeneca trial in United States remains on hold: CNBC
U.S. health secretary says AstraZeneca trial in United States remains on hold: CNBC  

NEW YORK (Reuters) - U.S. Health and Human Services Secretary Alex Azar said on Wednesday that the U.S. trial of AstraZeneca PLC's COVID-19 vaccine remains on hold while the U.S. Food and Drug Administration investigates a patient illness that shut down the global trial.

Azar said that the FDA's investigation, which has continued even after the trial has resumed outside of the United States, shows that the agency takes safety of the vaccine seriously.



(Reporting by Caroline Humer; Editing by Chizu Nomiyama)

COMMENTS

More Related News

Class Action Filed Against Zosano Pharma - ZSAN Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.
Class Action Filed Against Zosano Pharma - ZSAN Investors With Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.

PHILADELPHIA, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. continues its investigation of potential securities claims on behalf of investors of Zosano Pharma Corporation ("Zosano" or the "Company") (NASDAQ: ZSAN) to determine whether the Company engaged in securities fraud or other unlawful business practices. ZOSANO INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, THE COMPANY'S SECURITIES BETWEEN FEBRUARY 13, 2017 AND SEPTEMBER 30, 2020, BOTH DATES INCLUSIVE (THE "CLASS PERIOD"), AND SUFFERED LOSSES GREATER THAN $50,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM'S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT KEVIN CAULEY, DIRECTOR, BUSINESS DEVELOPMENT, (215) 792-6676, EXT....

AstraZeneca sells commercial rights to two drugs in $400 million deal
AstraZeneca sells commercial rights to two drugs in $400 million deal
  • US
  • 2020-10-30 07:26:59Z

AstraZeneca said it would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany's Cheplapharm Arzneimittel GmbH. AstraZeneca, which is among the front-runners in the race to develop a vaccine for the novel coronavirus, has been trying to focus on its cancer drug portfolio in a bid to streamline its business. The agreement with Cheplapharm supports AstraZeneca's strategy of focusing on newer medicines in main therapy areas, the drugmaker said.

Report: US knew of problems family separation would cause
Report: US knew of problems family separation would cause
  • World
  • 2020-10-29 18:22:48Z

Months before the Trump administration separated thousands of families at the U.S.-Mexico border, a "pilot program" in Texas left child-welfare officials scrambling to find empty beds for babies taken from their parents in a preview of bigger problems to come, according to a report released Thursday by congressional Democrats. Documents in the report suggest Health and Human Services officials weren't told by the Department of Homeland Security why shelters were receiving more children taken from their parents in late 2017. It has since been revealed that DHS was operating a pilot program in El Paso, Texas, that prosecuted parents for crossing the border illegally and took their...

APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an "Off-the-Shelf" Allogeneic Stem Cell Product for the Treatment of Diabetic Ulcers
APstem Therapeutics Announces Successful FDA INTERACT Meeting Regarding AP-Skin-01, an "Off-the-Shelf" Allogeneic Stem Cell Product for the Treatment of Diabetic Ulcers

Fremont, CA , Oct. 28, 2020 (GLOBE NEWSWIRE) -- APstem Therapeutics, Inc., a private biopharmaceutical company developing breakthrough stem cell therapies, today announced the completion of an INitial Targeted Engagement for Regulatory Advice on CBER ProducTs (INTERACT) meeting with the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT). The meeting, which included CBER OTAT staff together with the APstem team, focused on the development plan for AP-Skin-01, a novel "off-the-shelf" allogeneic stem cell product derived from adult pluripotent stem cells (APSCs™) for the initial treatment of diabetic...

Britain expects verdict on Pfizer
Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's: Times
  • US
  • 2020-10-28 23:26:12Z

Britain believes that the vaccine, which Pfizer is co-developing with Germany's BioNTech SE, could be ready to distribute before Christmas, the report said. Pfizer's Chief Executive Albert Bourla has previously said the company could release data on whether or not the vaccine works as early as this month. The U.S. drugmaker said this week if trials are successful the company expects to file for emergency authorization of the vaccine candidate from U.S. regulators shortly after it has enough safety data in late November.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US